By Cristin Flanagan
(Bloomberg) -- Sage Therapeutics jumps as much as 69% to $105.88 in pre-market trading after a key late-stage study in post-partum depression met its main goal. Marinus Pharmaceuticals, which recently announced plans to start a mid-stage trial in the same setting, climbs 33%.
NOTE: Another study of SAGE’s brexanolone in super-refractory status epilepticus (SRSE) failed to meet goals in Sept., raising the stakesfor today’s study to be successful, BofAML said at the time
“We expect shares to move up significantly on this data and for investors to start focusing on the major depressive disorder next,” Suntrust analyst Edward Nash writes in client note this morning; conservatively models $400m for I.V. brexanolone in PPD in 2026, an oral version may generate another $668m
MRNS is studying ganaxolone in PPD as well as SRSE, expects data from Phase 2 studies next year
NOTE: SAGE call 8am, 866-450-8683 pw 7592007
MRNS US Equity
Graphic Dashboard»
SAGE US Equity
Graphic Dashboard»
Related tickers:
Recent MRNS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:07:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:05:18 AM
- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 11:00:00 AM
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference • Business Wire • 05/02/2024 12:00:00 PM
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 • Business Wire • 05/01/2024 12:00:00 PM
- Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results • Business Wire • 04/15/2024 11:00:00 AM
- Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) • Business Wire • 04/05/2024 08:00:00 PM
- Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review • Business Wire • 03/27/2024 12:41:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:14:45 PM
- Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:05:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:06:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:05:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:05:24 PM
- Marinus Pharmaceuticals to Present at Upcoming Investor Conferences • Business Wire • 02/21/2024 12:00:00 PM
- Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 • Business Wire • 02/20/2024 12:00:00 PM
- Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) • Business Wire • 02/16/2024 09:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:18:21 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:07:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:18:04 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:06:58 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:04:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 05:13:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:28:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:27:58 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM